

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

LICENSING AGREEMENT WITH LUPENG PHARMA

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that on August 8, 2024, Hansoh (Shanghai) Healthtech Company Limited* (翰森(上海)健康科技有限公司), Jiangsu Hansoh Pharmaceutical Group Company Limited* (江蘇豪森藥業集團有限公司) and Shanghai Hansoh Biomedical Technology Company Limited* (上海翰森生物醫藥科技有限公司) (collectively, the “**Licensees**”), all being subsidiaries of the Company, entered into a license agreement (the “**Licensing Agreement**”) with Guangzhou Lupeng Pharmaceutical Co., Ltd.* (廣州麓鵬製藥有限公司) (“**Lupeng Pharma**”).

Pursuant to the Licensing Agreement, the Licensees obtained an exclusive license from Lupeng Pharma to develop and commercialize LP-168 within China (including Hong Kong, Macau and Taiwan). The Licensees will be responsible for the research and development (“**R&D**”), obtaining regulatory approval, manufacturing and commercialization of LP-168 in all non-tumor indications in China, and will pay an upfront payment and potential payments upon reaching R&D, regulatory and sales-based commercial milestones of up to RMB729 million, plus tiered royalties up to double-digit on future product sales.

ABOUT LP-168

LP-168 is a small molecule Bruton’s tyrosine kinase inhibitor (BTKi). As of the date of this announcement, Lupeng Pharma is conducting various clinical studies on LP-168, with the highest stage of development in China being a Phase II pivotal clinical trial of tumor.

ABOUT LUPENG PHARMA

Founded in 2018, Lupeng Pharma is an innovative pharmaceutical company focusing on malignant tumors, and autoimmune diseases. To the best knowledge and belief of the Company, Lupeng Pharma is independent of, and is not connected with, the Company and its connected person (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

LISTING RULES IMPLICATIONS

The upfront payment is expected to be recognized as R&D expenditure of the Company. Assuming that the transactions contemplated under the Licensing Agreement constitute “transactions” for the purpose of Chapter 14 of the Listing Rules, as all the applicable percentage ratios in respect of the payments payable under the Licensing Agreement are below 5%, the transactions contemplated under the Licensing Agreement do not constitute any notifiable transaction under Chapter 14 of the Listing Rules. Furthermore, the transactions contemplated under the Licensing Agreement do not constitute any connected transactions of the Company under Chapter 14A of the Listing Rules.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, August 8, 2024

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*